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Living organisms are continuously exposed to xenobiotics. The major phase of enzymatic
detoxiﬁcation in many species is the conjugation of activated xenobiotics to reduced glu-
tathione (GSH) catalyzed by the glutathione-S-transferase (GST). It has been reported that
some compounds, once transformed into glutathione S-conjugates, enter the mercapturic
acid pathway whose end products are highly reactive and toxic for the cell responsible for
their production. The cytotoxicity of these GSH conjugates depends essentially on GST
and gamma-glutamyl transferases (γGT), the enzymes which initiate the mercapturic acid
synthesis pathway. Numerous studies support the view that the expression of GST and
γGT in cancer cells represents an important factor in the appearance of a more aggressive
and resistant phenotype. High levels of tumor GST and γGT expression were employed
to selectively target tumor with GST- or γGT-activated drugs. This strategy, explored over
the last two decades, has recently been successful using GST-activated nitrogen mustard
(TLK286) and γGT-activated arsenic-based (GSAO and Darinaparsin) prodrugs conﬁrming
the potential of GSH-conjugates as anticancer drugs.
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INTRODUCTION
Glutathione (GSH) plays a myriad of roles in the body. It is a
major cellular antioxidant, involved in defense against oxidative
stress and redox signaling. GSH also modulates cell proliferation,
apoptosis, immune function, and ﬁbrogenesis (Lu, 2013). In can-
cer cells, GSH and enzymes of the mercapturic acid pathway play
a role in resistance to many chemotherapeutic drugs. However,
not all xenobiotics (including drugs) are conjugated/inactivated
by this pathway (Commandeur et al., 1995); some are in fact
activated into cytotoxic compounds. This review explores the
importance of the mercapturic acid pathway and the potential of
intra-tumor activation of old and recently discovered chemother-
apeutics. The expression patterns of participating enzymes of the
mercapturic acid pathway could theoretically be employed to drive
the activation of such compounds within the tumor.
The mercapturic acid pathway (Figure 1) involves the conju-
gation of the tripeptide, GSH, to xenobiotics (including drugs)
to render them more hydrophilic and facilitate their elimina-
tion. Although some spontaneous reactions could occur, the
cytosolic glutathione transferases (GST) catalyze the nucleophilic
Abbreviations: 6-MP, 6-mercaptopurine; 6-TG, 6-thioguanine (6-mercaptopurine
and 6-thioguanine); CAO, 4-[N-(S-cysteinylacetyl)amino]phenylarsonous acid;
cAVTP, cis-6-(2-acetylvinylthio)-purine; CPIC, p-chlorophenyl isocyanate; DMAC,
dimethylarsino-cysteine; DMACG, dimethylarsino-cysteinylglycine; EGFR, epider-
mal growth factor receptor; GSH, glutathione; GCAO, 4-[N-(S-cysteinylglycyl-
acetyl) amino] phenylarsonous acid; γGT, gamma-glutamyl transferase; GSAO,
[4-(N-(S-glutathionylacetyl) amino)phenylarsonous acid]; GS-cAVTP, glu-
tathione s-cis-6-(2-acetylvinylthio)-purine; Glu, glutamate; Gly, glycine;
GS-tAVTG, glutathione s-trans-6-(2-acetylvinylthio)-guanine; PENAO,
4-(N-(S-penicillaminylacetyl)-amino)phenylarsonous acid; SCPG, S-(N-p-
chlorophenylcarbamoyl) glutathione; tAVTG, trans-6-(2-acetylvinylthio)-guanine.
conjugation of GSH with a wide spectrum of electrophiles
(Armstrong, 1997). Being the ﬁrst step in the metabolism and
eventual removal of the drug from the body, GST is associated
with chemotherapeutic resistance since exposure to these drugs
is often associated with induction of GST, especially GST P1-1
(Dahllof et al., 1987; Hamada et al., 1994; Hao et al., 1994). The
GSH-conjugated compounds generated are then actively pumped
out of the cell by numerous members of the MRP/ABCC family,
which appear to have broad and partially overlapping substrate
speciﬁcity (Ballatori et al., 2009). At the cell surface, the ﬁrst step in
the catabolism of GSH-conjugates is catalyzed by the membrane-
bound gamma-glutamyl transferase (γGT) which removes the
GSH γ-glutamyl group and transfers it to appropriate acceptors.
Similar to what has been described for GST,γGT is also considered
to be part of a resistance phenotype. Themain reason for this is the
role that γGT plays in maintaining appropriate GSH levels in the
cells for xenobiotic detoxiﬁcation by conjugation (Pompella et al.,
2006). The newly formed cysteinylglycine S-conjugates are further
processed by dipeptidases/aminopeptidases to remove the glycyl
group and produce cysteine S-conjugates. These compounds then
re-enter the cell via various transporters including organic anion
transport polypeptides and cystine/cysteine importers (Hinchman
et al., 1998; Budy et al., 2006; Dilda et al., 2008, 2009; Garnier et al.,
2014). In the cytosol,N-acetyl transferases createmercapturic acid
versions of the xenobiotics which are generally more polar and
more water soluble than the parental compound. At this point, the
compounds are generally non-toxic and excreted from the body
through bile or urine. Alternatively, instead of acetylation, some
compounds can be converted by cysteine S-conjugate β-lyase to
produce an unstable and highly reactive thiol.
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FIGURE 1 | Detoxification of xenobiotic through the mercapturic acid
synthesis pathway. X, xenobiotic; GS-X, GSH-conjugated version of X; CG-X,
cysteinylglycyl-X; C-X, cysteinyl-X; NAC-X, mercapturic acid version of X;
−S-X, highly reactive thiol version of X; GST, glutathione S-transferase, γGT,
gamma-glutamyl transferase; Pept., peptidase; Import., peptide transporter or
cystine/cysteine importer.
There are several examples of drugs becoming toxic/bioactive
following their conjugationwithGSH.Trichloroethylene ismetab-
olized to form [S-(1,2-dichlorovinyl)GSH], which is the ﬁrst step
in the GSH metabolism pathway. In vitro (Lash et al., 1986; Chen
et al., 1990; Cummings and Lash, 2000) and in vivo (Terracini and
Parker, 1965; Elfarra et al., 1986), the downstream metabolites
of GSH S-dichlorovinyl, such as N-acetyl-S-(1,2-dichlorvinyl)-
L-cysteine and S-(1,2-dichlorovinyl)-L-cysteine, induce toxicity
towards the cells responsible for their production (Spencer and
Schaumburg, 1985; Patel et al., 1993). Consistent with what
was observed with trichloroethylene, the GSH-S-conjugate of
4-hydroxynonenal (HNE) causes a loss in cell viability in γGT-
expressing cells (Enoiu et al., 2002). This effect was attributed to
the cysteinylglycine S-conjugate of HNE (Calonghi et al., 2002;
Cerbone et al., 2007; Pettazzoni et al., 2011).
The expression of several enzymes involved in the mercapturic
acid pathway (notably GST and γGT) is induced in cancer cells
and particularly drug resistant cancer cells (Table 1). The speciﬁc
expression of these enzymes involved in the local production of
cytotoxic/bioactive drugs has been exploited to design and develop
various types of anticancer prodrugs. This review describes the
enzymes involved in drug activation in the order they participate
along the mercapturic acid pathway, GST, γGT, and β-lyase. The
potential to exploit the induced expressionof these enzymes as pre-
dictive markers and the opportunity this presents for drug design
is discussed.
BIOACTIVATION OF CANCER COMPOUNDS BY GST
Glutathione transferases (EC2.5.1.18) are a superfamily of dimeric
detoxiﬁcation enzymes which contribute to the cellular biotrans-
formation of electrophilic compounds (Mannervik et al., 2005).
They provide protection against genotoxic and carcinogenic effects
of numerous substances of both xenobiotic and endogenous ori-
gins. The essential role of GST is to catalyze the conjugation of
GSH with a wide variety of compounds, including drugs, result-
ing in the formation of the corresponding GSH-conjugates and
subsequently facilitate their clearance from the body. In humans,
various isoforms of GST are present in virtually all tissues with the
liver exhibiting the highest cytosolic GST activity level followed by
kidney, lung, and intestine (Paciﬁci et al., 1988).
GST AND CANCER
Although GST detoxifying activity protects cells from endogenous
toxic products, it also blunts the effectiveness of certain anticancer
drugs (O’Brien and Tew, 1996). GST and GSH are frequently
elevated in many tumors relative to surrounding healthy tissue
(Howie et al., 1990). Isoenzyme GST P1-1 is notably induced in
lung, colon, and stomach cancers and was found to be implicated
in cellular resistance to chemotherapeutic agents (Dahllof et al.,
1987; Hamada et al., 1994; Hao et al., 1994).
The polymorphism in GSTM1 and GSTT1 genes, leads to
complete lack of activity of their corresponding enzymes and is
responsible for poor elimination of carcinogenic substances which
are potential sources of reactive oxygen species (Rebbeck, 1997;
Kumar et al., 2011). This polymorphism has been associated with
increased risk of benign prostatic hyperplasia and prostate cancer
(Rebbeck et al., 1999) and can be a useful biomarker to iden-
tify patients at higher risk for fatal prostate cancer (Agalliu et al.,
2006; Liu et al., 2013). In prostate, but also breast, endometrial
and hepatocellular carcinomas, another early tumor marker is
GSTP1 promoter methylation which is detected at various per-
centages of clinical samples (Esteller et al., 1998; Zhong et al.,
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Table 1 | Activity and expression levels of glutathione-S-transferase and gamma-glutamyl transferase in tumor tissues.
Tumor Glutathione S-transferase Gamma-glutamyl transferase
Activity or expression
vs. normal tissue
Reference Expression in tumor tissue Reference
Liver ↓ 0.50 Howie et al. (1990) ++ Tsutsumi et al. (1996), Hanigan et al.
(1999a)↓ Pol. M1, T1 Song et al. (2012)
Kidney ↓ 0.27–0.44 Di Ilio et al. (1987), Wang et al. (1989) ++ Hanigan et al. (1999a)
↓ Pol. P1, M1, T1 Ahmad et al. (2012) ↑ vs. normal tissue (activity) Arai et al. (1995)
Esophagus ↑ 5.75 Tsuchida et al. (1989) + Hanigan et al. (1999a)
↓ Expression P1 Wang et al. (2010) ↑ vs. normal tissue
(expression and activity)
Fiala et al. (1980)
Stomach ↑ 1.36–1.66 Howie et al. (1990), Peters et al.
(1990)
± Hanigan et al. (1999a)
Colon ↑ 1.37–4.3 Tsuchida et al. (1989), Moorghen
et al. (1991)
+ Hanigan et al. (1999a)
↑ vs. normal tissue
(expression and activity)
Fiala et al. (1980), Murata et al.
(1997)
Pancreas ↓ Pol. M1, T1 Fan et al. (2013) + Hanigan et al. (1999a), Ramsay et al.
(2014)
Lung ↑ 1.83–2.63 Di Ilio et al. (1987), Howie et al.
(1990)
± Hanigan et al. (1999a)
↑ vs. normal tissue
(expression)
Tateishi et al. (1976), Dempo et al.
(1981), Blair et al. (1997)
Thyroid ↓ Pol. P1, M1, T1 Gaspar et al. (2004), Li et al. (2012) + Hanigan et al. (1999a)
Breast → 0.85–1.33 Forrester et al. (1990),
Howie et al. (1990)
++ Durham et al. (1997), Hanigan et al.
(1999a),
↓ Pol., methyl. P1 Saxena et al. (2012) ↑ vs. normal tissue
(expression and activity)
Fiala et al. (1980), Bard et al. (1986)
Ovary ↑ Expression Hetland et al. (2012) + Paolicchi et al. (1996), Hanigan et al.
(1999a, 1994), Grimm et al. (2013)
Prostate ↓ Pol. P1, M1, T1 Moskaluk et al. (1997), Rebbeck
et al. (1999)
++ Hanigan et al. (1999a)
↓ Methyl. P1 Esteller et al. (1998) ↑ vs. normal tissue
(expression and activity)
Fiala et al. (1980)
Urinary bladder ↑ 5.17 Lafuente et al. (1990) ↑ vs normal tissue (expression
and activity)
Fiala et al. (1980)
→ Expression Og˘uztüzün et al. (2011)
For GST, arrows indicate if the measured activity or expression is increased (↑), decreased (↓) or stable (→) in comparison with normal tissue. Values are the ratio of
GST activity in tumor tissue with GST activity in normal tissue. Pol. refers to polymorphism of GST genes responsible for the loss of activity of GST P1 (P1), GST M1
(M1), or GSTT1 (T1) isoenzymes. Methyl. refers to DNA methylation in the promoter region of GSTP1 gene responsible for epigenetic silencing of this isoenzyme. For
gamma-glutamyl transferase, arrows indicate that the measured activity or expression is increased (↑) in comparison with normal tissue. The signs + and ± indicate
the level of γGT expression in tumor tissues measured by immunohistochemistry.
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2002; Chan et al., 2005; Lee, 2007; Yoon et al., 2012). The epi-
genetic silencing of GSTP1 provides a mechanism of resistance
which makes tumors with GSTP1 promoter methylation bad can-
didates for the GST-activated anti-cancer prodrugs presented in
this review. However, recent studies demonstrated that it is pos-
sible to re-sensitize tumors using a combination of molecules
speciﬁcally reverting the aberrant DNA methylation in cancer cells
(through drugs inhibiting DNA methyltransferase activity) and
cytotoxic drugs (Plumb et al., 2000; Cheng et al., 2003; Sabatino
et al., 2013).
GST ANTICANCER PRODRUGS
An approach to solving drug resistance due to over expression
of GST is to design speciﬁc GST inhibitors (Ruzza et al., 2009).
Alternatively, GST overexpression offers the opportunity to tar-
get resistant tumors with GST-activated prodrugs. This type of
compound undergoes GST-catalyzed breakdown to release locally
cytotoxic metabolites and thereby attenuate off target adverse
side effects. Amongst these prodrugs, two categories can be
distinguished.
The ﬁrst category consists of prodrugs containing a GSH or
GSH-like structure for which a β-elimination reaction, catalyzed
by GST, releases a cytotoxic compound. This includes compounds
such as nitrogen mustards, which have the property to alky-
late DNA after further transformation: TLK286 (canfosfamide,
TELCYTATM) and analogs (Lyttle et al., 1994; Satyam et al., 1996;
Dourado et al., 2013; Figure 2A). TLK286 showed interesting
in vitro and in vivo antiproliferative activity on cells with high GST
P1-1 expression as a result of selection for doxorubicin, cyclophos-
phamide, and platinum resistance (Morgan et al., 1998; Townsend
et al., 2002). In murine xenografts, tumor growth inhibition, or
regression in response toTLK286was positively correlatedwith the
level of GST P1-1 expression (Morgan et al., 1998). Several clini-
cal trials demonstrated that TLK286 was active and safe to use in
combination treatment regimenswith standard chemotherapeutic
agents, including platinums, taxanes, and anthracyclines. Note-
worthy, clinical efﬁcacy was observed with both relapsed patients
with ovarian and non-small cell lung cancers, and in the ﬁrst-line
treatment setting in non-small cell lung cancer patients (Sequist
et al., 2009; Vergote et al., 2010).
The second category regroups prodrugs non-structurally
related to GSH. However, their activation by GST involves the
production of an intermediate GSH-conjugate.
– In this category, cis-6-(2-acetylvinylthio)-purine (cAVTP) and
trans-6-(2-acetylvinylthio)-guanine (tAVTG) contain active
thiopurines (6-mercaptopurine and 6-thioguanine, respec-
tively) liberated intracellularly after GSH-conjugation cat-
alyzed by GST M1-1, M2-2, and A4-4, but not GST
P1-1 (Gunnarsdottir et al., 2002; Eklund et al., 2007;
Figure 2B). Both compounds exhibited a remarkable growth-
inhibitory activity towards leukemic and melanoma cells
(Gunnarsdottir and Elfarra, 2004). In vivo, on the contrary
to what was observed following the administration of bioac-
tive end products (6-mercaptopurine and 6-thioguanine), no
reduction of circulating white blood cells was observed upon
FIGURE 2 | Mechanisms of activation of GST prodrugs. TLK286 (A) has a
GSH-like moiety in its structure, in contrast, all other presented drugs are
conjugated with GSH during their process of activation by GST. (B) for
cAVTP, GS-cAVTP, and 6-MP, R1: cis-butenone; R2: H. For tAVTG, GS-tAVTG
and 6-TG, R1: trans-butenone; R2: NH2. (D) for sulfonamine compounds,
R1: bombesin or aryl derivatives; R2: CN or CF3. (E) for PABA/NO, R1:
NMe2; R2: 4-carboxy-N -methylanilinyl. For JS-K, R1: 1-carboxyethyl-4
piperazinyl, R2: H.
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administration of cAVTP and tAVTG (Gunnarsdottir et al.,
2002).
– Using a similar strategy, exocyclic enones displaying antitu-
mor activity were produced by a GSH-dependent reaction
catalyzed by GST (Hamilton et al., 2002, 2003). COMC-
6 (2-crotonyloxymethyl-2-cyclohexenone) is a potent anti-
tumor agent against both murine and human tumors
in culture and in tumor-bearing mice (Aghil et al.,
1992).
– Diarylsulfonylureas are a class of antitumor agent with inter-
esting therapeutic efﬁcacy against a wide range of cancers
(Howbert et al., 1990; Mohamadi et al., 1992). Sulofenur [(N-
(5-indanesulfonyl)-N ′-(4-chlorophenyl)urea, LY18664], the
prototypic member of this class (Figure 2C), was evalu-
ated in clinical trials on a variety of patients with kid-
ney (Mahjoubi et al., 1993), ovary (O’Brien et al., 1992),
breast (Talbot et al., 1993), lung (Munshi et al., 1993), and
stomach (Kamthan et al., 1992) cancers. It appeared that
sulofenur can undergo metabolic biotransformation to yield
the GSH-conjugate of p-chlorophenyl isocyanate [S-(N-p-
chlorophenylcarbamoyl) GSH, SCPG; Jochheim et al., 2002].
Whether a direct involvement of GST is necessary or not
in the production of this GSH-conjugate remains unclear.
However, it was clearly demonstrated that SCPG is fur-
ther processed through the mercapturic acid pathway to
the corresponding N-acetylcysteine conjugate [N-acetyl-S-
(p-chlorophenylcarbamoyl)cysteine, NACC], which possesses
comparable anticancer activity to the parent compound. The
GSH- and cysteine-conjugates produced are susceptible to
thiol exchange reactions and may act as carbamoylating agents
towards biomacromolecules (Day et al., 1996; Guan et al., 2002).
NACC, whose mechanism of action remains unclear, demon-
strated selective anticancer activity, and low toxicity, which
make NACC and its analogs promising anticancer agents (Chen
et al., 2011).
– Another approach was to use the sulphonamidase activ-
ity of GST. GST catalyzes the GSH-mediated hydrol-
ysis of sulfonamide bonds, releasing GST competitive
inhibitors such as benzylsulfonyl-GSH or S-benzyl-GSH
(Koeplinger et al., 1999; Zhao et al., 1999; Axarli et al., 2009;
Figure 2D).
– Finally, electrophilic diazenium diolates were designed as
prodrugs for spontaneous nitric oxide (NO) release at phys-
iological pH, after a reaction with GSH catalyzed by GST.
Essentially two compounds were studied. PABA/NO [(O2-(2,4-
dinitro-5-(N-methyl-N-4 carboxyphenylamino)phenyl) 1-
N,N-dimethylamino)diazen-1-ium-1,2-diolate; Findlay et al.,
2004] and JS-K [O2-(2,4-dinitrophenyl) 1-[(4-ethoxycarbonyl)
piperazin-1-yl]diazen-1-ium-1,2-diolate; Shami et al., 2003]
were selectively activated by GST M1 and GST A1, respectively,
and produced abundant NO in the tumor and contributed to
chemotherapy by GSH consumption, DNA synthesis inhibi-
tion and inhibition of enzymes responsible for cellular damage
repair (Figure 2E). PABA/NO and JS-K demonstrated antitu-
mor activity inmice bearing humanovarian carcinoma (Findlay
et al., 2004) and prostate carcinoma (Laschak et al., 2012) or
multiple myeloma (Kiziltepe et al., 2007), respectively. Recently,
new generations of more stable and potent GST-activated
NO prodrugs have been developed (Liu et al., 2012; Fu et al.,
2013).
GLUTATHIONE S -DERIVATIVES ACTIVATED BY γGT AND
PEPTIDASES
Gamma-glutamyl transferase (EC2.3.2.2) catalyzes the transpepti-
dation and hydrolysis of the γ-glutamyl group of GSH and related
compounds to an acceptor molecule, including water, amino
acids, and peptides. It is found on the plasma membrane, fac-
ing extracellularly, playing an essential role in the maintenance of
intracellular cysteine (Moriarty-Craige and Jones, 2004). Consid-
ering GSH’s important role as a cellular antioxidant, γGT has
traditionally been considered a component of the cell’s oxida-
tive stress defenses. However, the range of γGT substrates has
expanded considerably, now including a range of GSH conju-
gates, leukotriene C4 (LTC4), S-nitroso-GSH and GSH adducts
of xenobiotics, suggesting diverse roles for γGT.
High expression of γGT is commonly found on cells involved
in transport, on the luminal surface of secretory and absorp-
tive cells. Its highest expression is on the luminal surface of the
proximal tubules in the kidney, whilst the bile ducts, bile canali-
culi, and endothelial cells of the nervous system capillaries also
have high expression (Shiozawa et al., 1989; Hanigan and Frierson,
1996).
Oxidative stress has been shown to induce γGT expression
(Kugelman et al., 1994; Knickelbein et al., 1996; Liu et al., 1998;
Borud et al., 2000; Roomi et al., 2006). High γGT expression pro-
tects melanoma cells from hydrogen peroxide or ascorbic acid
induced oxidative stress (Giommarelli et al., 2008). It also allows
the cells to maintain their intracellular GSH levels and subse-
quently respond to oxidative stress. Conversely, γGT has been
demonstrated to have pro-oxidant effects. Combined with metal
ions (iron or copper), γGT can induce lipid peroxidation (Stark
et al., 1993; Stark and Glass, 1997). γGT has been linked to reactive
oxygen species generation in cells (Drozdz et al., 1998; Del Bello
et al., 1999; Paolicchi et al., 2002).
γGT AND CANCER
Gamma-glutamyl transferases expression has been shown to
be increased in numerous cancers. Increased levels have been
observed in cancer of the ovary, liver, lung, and breast, and in
melanoma and leukemia (Fujisawa et al., 1976; Gerber and Thung,
1980; Dempo et al., 1981; Bard et al., 1986; Corti et al., 2010; Mareš
et al., 2012). In many cases the γGT levels are higher in the cor-
responding primary tumor (Maellaro et al., 2000). An extensive
study by Hanigan et al. (1999a) scored the expression of γGT
in a variety of tumors. Carcinomas in particular express γGT,
with carcinomas of the kidney, liver, and prostate showing strong
expression (Hanigan et al., 1999a). Furthermore, some carcinomas
of the breast, ovary, uterus, and pancreas were shown to express
γGT. On the contrary, non-epithelial malignancies and sarcomas
rarely expressed γGT.
Gamma-glutamyl transferases has been considered an early
marker of neoplastic transformation. Many early studies have
demonstrated in in vivo models the appearance of γGT expres-
sion in areas previously negative following exposure to carcinogens
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(Pompella et al., 2006). The underlying mechanism of this phe-
nomenon remains unclear. A genome-wide analysis of pancreatic
cancer implicated GGT1 as playing a role in carcinogenesis
(Diergaarde et al., 2010). The proto-oncogene KRAS was shown
to be involved in the upregulation of γGT expression. Recently,
Moon et al. (2012) have demonstrated that KRAS transformed
prostate epithelial cells are more resistant to hydrogen peroxide
induced free-radicals than non-transformed cells. They observed
an upregulation of GGT2 in the KRAS transfected cells and con-
ﬁrmed its role in resistance to hydrogen peroxide treatment. This
has also been observed in colon carcinoma cells where radiation
induced γGT activity was mediated through Ras pathway (Pankiv
et al., 2006).
The early appearance of γGT in neoplasms suggests the poten-
tial for γGT to play a role in tumor progression. γGT has been
shown to give cells a growth advantage in vitro and in vivo. High
expression of γGTprovides cells with greater quantities of cysteine
through the breakdown of extracellular GSH (Gerber and Thung,
1980; Hanigan, 1995; Hochwald et al., 1996). This explains the
difference in growth rates of cells when moved from the in vitro
setting to mice, where extracellular GSH and cysteine is limited
in vivo. In clones of melanoma cells, the extent of γGT expression
was shown to be proportional to the invasive ability of the clone
(Supino et al., 1992).
γGT AND DRUG RESISTANCE
Beyond its differential expression in cancer, γGT is considered to
be part of a resistance phenotype (Pompella et al., 2006). Themain
reason for this is the role that γGT plays in maintaining GSH levels
within the cell. GSH plays an important part in the detoxiﬁcation
of xenobiotics by binding to a range of agents and this allows for
GSH mediated expulsion of these compounds from the cell.
The relationship between γGT and chemotherapy resistance is
demonstrated by a number of experiments showing that trans-
fection with γGT both in vitro and in vivo leads to resistance to
members of the platinum drug family, and in particular to cis-
platin (Hanigan et al., 1999b; Daubeuf et al., 2002; Franzini et al.,
2006). Further evidence of the relationship comes from biopsies
from ovarian adenocarcinoma patients before and after treatment
(cisplatin, chlorambucil, and 5FU). Cells grown from biopsies
taken before and after treatment, showed a 6.5-fold increase in
γGT activity following treatment (Lewis et al., 1988). However,
Schäfer et al. (2001) found no direct link between γGT and resis-
tance, despite an evident growth advantage forγGToverexpressing
cells.
Another proposed mechanism for platinum drug resistance is
the formation of adducts between the platinum drug and the
cysteinyl-glycine product of γGT. These complexes have poor
ability to cross the cell membrane; as a result the platinum
drug rarely reaches its target (DNA). These adducts have been
described in the extracellular media of γGT overexpressing cells
and the plasma of patients treated with oxaliplatin (Daubeuf
et al., 2002, 2003; Paolicchi et al., 2003; Jerremalm et al., 2006;
Corti et al., 2010).
Gamma-glutamyl transferases has also been implicated in resis-
tance to radiation therapy. In lymphoid cells, γGT plays a role
in maintaining the intracellular GSH levels that are essential for
protection against radiation (Jensen andMeister, 1983). Inhibition
of γGT in melanoma cells signiﬁcantly increased the radiosensi-
tivity of a high γGT variant (Prezioso et al., 1994b). In CC531, a
colon cancer cell line, γGT was upregulated in a time and dose-
dependent manner to irradiation. This increase in γGT activity
was attributed to de novo synthesis of the mRNA. It was fur-
ther demonstrated that signaling through the Ras pathway was
responsible for this increase (Pankiv et al., 2006).
HIGH γGT EXPRESSION AND INTRATUMOR DRUG ACTIVATION
The high expression of γGT within aggressive and drug-resistant
tumors implies that GSH-conjugated prodrugs, activated at the
cell surface by γGT, should be particularly effective against γGT-
positive tumors. The metabolism of these compounds by γGT
positive tumor cells should produce high local concentrations
of bioactive and membrane permeable metabolites that would
then block tumor cell proliferation and eventually tumor growth.
Increasing the concentration of active metabolites at the tumor
site, will subsequently limit the concentration of active drug at
other sites, reducing side effects.
Arsenic-based GSH-conjugates
GSAO [4-(N-(S-glutathionylacetyl)amino)phenylarsonous acid]
and Darinaparsin (ZIO-101; S-dimethylarsino-GSH) are arsenic-
based GSH-conjugates with demonstrated antitumor activity
evaluated in clinical trials (Donet al., 2003;Dilda et al., 2005b;Diaz
et al., 2008; Tsimberidou et al., 2009; Hosein et al., 2012; Horsley
et al., 2013). For both drugs, extracellular γGT activity is an essen-
tial and limiting step in their activation into membrane permeable
compounds (Dilda et al., 2008; Garnier et al., 2014). Indeed, it has
recently been demonstrated that tumor γGT could be used for
therapeutic delivery (Ramsay et al., 2014).
GSAO. 4-(N-(S-glutathionylacetyl)amino)phenylarsonous acid is
a prospective cancer drug and has just completed a phase I
dose escalation study in patients with solid tumors refractory to
standard therapy (Horsley et al., 2013). Treatment was very well
tolerated. Of 34 patients, 20 were evaluated for response (receiv-
ing two or more cycles of GSAO). Whilst no patient exhibited
an objective response, eight had stable disease, with one patient
having stable disease for 18 weeks.
4-(N-(S-glutathionylacetyl)amino)phenylarsonous acid con-
sists of a phenylarsenoxide moiety attached by an N-acetyl linker
to the cysteine thiol of reduced GSH (Figure 3). The pheny-
larsenoxide group is the active moiety, imparting to GSAO its
activity by crosslinking closely spaced protein thiols and form-
ing a high afﬁnity ring structure between its arsenic and the
thiols (Donoghue et al., 2000). GSAO speciﬁcally targets prolif-
erative endothelial cells, which consequently starves the tumor
of the nutrients required to support its expanding growth (Don
et al., 2003; Dilda et al., 2005b). The GSH moiety contributes to
the transport of GSAO in and out of the cell (Dilda et al., 2008,
2005b).
4-(N-(S-glutathionylacetyl)amino)phenylarsonous acid in its
original form is essentially membrane impermeable. Upon
reaching the cell surface the γ-glutamyl group is cleaved
by γGT (Dilda et al., 2008), generating the dipeptide
form, 4-(N-(S-cysteinylglycylacetyl) amino) phenylarsonous acid
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FIGURE 3 | Activation process of GSAO and subsequent activity on
endothelial cell proliferation. (A) GSAO activation by γGT and peptidase.
(B) Pancreatic tumor cell γGT activity positively correlates with
GSAO-mediated proliferation arrest of endothelial cells in a transwell model.
Pancreatic adenocarcinoma cells are represented by circles and normal and
tumor-activated pancreatic stellate cells by squares. BxPC-3 pancreatic tumor
cells transfected with γGT are represented as triangles. (C) Model of GSAO
activation by tumor γGT (from Ramsay et al., 2014).
(GCAO). GCAO is then able to enter the cell through
organic anion transporters (OATPs). Within the cell fur-
ther processing by dipeptidases likely occurs, resulting in the
formation of the single amino acid form of GSAO, 4-(N-(S-
cysteinylacetyl)amino)phenylarsonous acid (CAO; Dilda et al.,
2008; Figure 3A).
The phenylarsenoxide moiety of CAO has been conﬁrmed
to crosslink the cysteine residues 57 and 257 of the adenosine
nucleotide translocator (ANT; Park et al., 2012). ANT is the most
abundant protein found on the inner mitochondrial membrane
and it is responsible for the exchange of matrix ATP for cytosolic
ADP across the inner mitochondrial membrane. Disruption of its
function has been shown to have major impacts on mitochondrial
integrity and cell survival (Halestrap et al., 2002; McStay et al.,
2002; Don et al., 2003). The calcium-dependent binding of CAO
to ANT induces a conformational change (Halestrap et al., 2002)
which results in the opening of the mitochondrial permeability
transition pore (MPTP) and allows the equilibration of small
solutes and the release of pro-apoptotic proteins from the inter-
membrane space. The equilibration that results leads to a collapse
of the proton-motive force across the membrane and a colloid
osmotic pressure that causes massive swelling of the mitochondria
(McStay et al., 2002).
There are a number of factors that inﬂuence GSAO activity:
the level of expression of the enzyme responsible for its activation
(γGT); intracellular GSH levels; and the expression of the multi-
drug resistance association proteins, ABCC1 (MRP1) and ABCC2
(MRP2). The combination of low intracellular GSH levels and
low expression of ABCC1 and ABCC2 in proliferative endothelial
cells accounts for GSAO selectivity and subsequently for GSAO
anti-angiogenic properties (Dilda et al., 2005a,b; Park and Dilda,
2010).
Pancreatic tumors display the most prominent stro-
mal/desmoplastic reaction of all epithelial tumors (Apte and
Wilson, 2012). Knowing that pancreatic tumorigenesis has been
associated with expression of γGT by both cancer and tumor-
associated stellate cells (Ramsay et al., 2014), Ramsay et al. (2014)
have explored the utility of this enzyme in deliveringGSAO to pan-
creatic ductal adenocarcinoma. They demonstrated that human
pancreatic tumor and stellate cells activate/process GSAO into its
active metabolite and that γGT activity positively correlates with
GSAO-mediated proliferation arrest of co-cultured endothelial
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cells (Figure 3B). Importantly, tumor γGT activity positively
correlates with GSAO-mediated inhibition of pancreatic tumor
angiogenesis and tumor growth in mice.
4-(N-(S-penicillaminylacetyl)-amino)phenylarsonous acid
(PENAO), a cysteine mimetic analog of the cysteine-S-conjugate
metabolite of GSAO has been investigated. In this compound,
penicillamine replaces the cysteine moiety of CAO. PENAO was
shown to have the same molecular target as GSAO (Dilda et al.,
2009; Park et al., 2012). By bypassing the cell surface pro-
cessing of GSAO, PENAO accumulated 85 times faster in cells
(Dilda et al., 2009). This corresponds to an increase in anti-
proliferative capacity on a variety of endothelial and cancer
cell lines. Interestingly, PENAO has a strong anti-proliferative
activity against glioblastoma cell lines (Chung et al., 2011) and
primary isolates of diffuse intrinsic pontine glioma (Tsoli et al.,
2013). In vivo, PENAO demonstrated preclinical activity with-
out signs of toxicity in tumor models of glioblastoma (Chung
et al., 2013) and pancreatic carcinoma (Dilda et al., 2009). In the
later model, PENAO was approximately 20-fold more efﬁcacious
than GSAO (Dilda et al., 2009). Large scale animal toxicity studies
demonstrated that PENAO was as well tolerated as GSAO, sug-
gesting an interesting therapeutic window for this compound.
PENAO is currently being tested in a clinical Phase I trial in
patient with solid tumors refractory to standard chemother-
apy. PENAO is another example of a mercapturic acid pathway
metabolite with antitumor properties. However, the lack of pro-
cessing by γGT removes the targeting advantage presented by
GSAO.
Darinaparsin. S-dimethylarsino-GSH (Darinaparsin; ZIO-101)
is an organic arsenical compound currently in clinical develop-
ment. It has been tested in Human with hematologic malignancies
(Hosein et al., 2012; Nielsen et al., 2013) as well as solid tumors
(Tsimberidou et al., 2009; Wu et al., 2010). Signiﬁcantly more
potent and better tolerated than arsenic trioxide, Darinaparsin
showed encouraging responses in T-cell lymphoma (Hosein et al.,
2012) andAML (Nielsen et al., 2013) patients. However, in a phase
II evaluation of the compound in hepatocellular carcinoma, no
objective response was shown (Wu et al., 2010).
Darinaparsin belongs to the class of organic arsenical com-
pounds that are generally considered less toxic than inorganic
ones (Waxman andAnderson, 2001; Dilda and Hogg, 2007). It was
synthesized by conjugating GSH to dimethyl arsenic (Figure 4).
Darinaparsin shares some characteristics with other arsenicals but
has also unique properties. As do other arsenicals, it induces
G2/M cell cycle arrest and triggers apoptosis through disruption
of mitochondrial functions and JNK activation and is respon-
sible for reactive oxygen species production (Diaz et al., 2008).
However, unlike arsenic trioxide, GSAO (Dilda et al., 2005b) or
PENAO (Dilda et al., 2009), Darinaparsin activity is unaffected
by the expression of ABCC1 (MRP-1), modulation of GSH levels
(Diaz et al., 2008) and heme-oxygenase inhibition (Garnier et al.,
2013).
Darinaparsin was characterized in vitro as a potent inducer
of growth arrest and apoptosis in a range of hematologic malig-
nancies such as acute promyelocytic leukemia (APL), acute lym-
phoblastic leukemia, B cell lymphoma, and multiple myeloma
(Diaz et al., 2008; Matulis et al., 2009). In contrast to arsenic
trioxide (Lallemand-Breitenbach et al., 2012) and like PENAO
and melarsoprol (Chen et al., 2003), Darinaparsin, at con-
centrations that induce apoptosis, does not induce PML/RAR
degradation in APL cells. In the context of solid cancer,
Darinaparsin was found to have preferential cytotoxic and
radiosensitizing effects as compared with normal cells both
in vitro and in a clinically relevant model (Tian et al., 2012,
2013).
It was recently demonstrated that Darinaparsin, which is essen-
tially a GSH S-conjugate of dimethylarsenic, needs to be processed
at the cell surface before exerting its activity on various cancer cells.
The GSH moiety of the drug has to be processed by γGT before
further processing by dipeptidases to generate dimethylarsino-
cysteine (DMAC), a cysteine S-conjugate which is imported via
cystine transporters (Garnier et al., 2014; Figure 4). Whether
DMAC could be subsequently transformed intracellularly into (i)
a highly reactive and cytotoxic thiol through β-lyase activity or
(ii) dimethylarsenite/dimethylarsenate is not known. Similarly to
what was observed in the case of GSAO and CAO (Dilda et al.,
2008), Garnier et al. (2014) demonstrated that DMAC recapit-
ulates the effects of Darinaparsin and that γGT is the ﬁrst and
limiting step in the activation of the drug. They also linked Dari-
naparsin efﬁcacy to the level of expression of cystine/cysteine
importing systems in cancer cells.
S-nitrosoglutathione
S-nitrosoglutathione (GSNO) is the S-nitrosated derivative of
GSH and is thought to be a critical mediator of the downstream
signaling effects of NO (Broniowska et al., 2013). GSNO plays
roles as a carrier for NO and in protein S-nitrosation or S-
glutathiolation (Broniowska et al., 2013). GSNO can be cleaved by
γGT (Hogg et al., 1997; Angeli et al., 2009; Bramanti et al., 2009),
generating S-nitrosocysteinylglycine and releasing NO in vitro.
GSNO has been tested in a number of clinical trials, the majority
focusing on the cardiovascular effects of GSNO as a NO donor
(Broniowska et al., 2013). As do other NO-donating compounds,
GSNO induces oxidative stress and initiates apoptosis (Turchi,
2006). GSNO promotes NO-induced apoptosis in colon carci-
noma cell lines through depletion of intracellular GSH and the
release of NO, (Ho et al., 1999; Liu et al., 2003). In a variety
of cell lines, GSNO treatment combined with a MEK inhibitor
was shown to inhibit the proliferation and invasive phenotype
of the cells (Furuhashi et al., 2012). In T and B lymphocytes
the anti-proliferative effect of GSNO was dependent on γGT
activity (Henson et al., 1999). The anti-proliferative activity of
GSNO, combined with the overexpression of γGT in tumor
cells, suggests the possibility of its utility in cancer therapy. This
requires further understanding of the roles that NO plays in
cancer.
In the light of the promising results obtained, notably with
the arsenical-based GSH-conjugates, it appears that tumor γGT
could potentially be employed in drug targeting and delivery. In
addition to cleavage of the γ-glutamyl from a GSH moiety, γGT
can also catalyze the cleavage of γ-glutamylmoieties from a variety
of compounds. This property along with tissue/tumor expression
of γGT was used to develop γ-glutamyl prodrugs.
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FIGURE 4 | Activation process of Darinaparsin.
γ-glutamyl conjugates and N acetyl γ-glutamyl conjugates
Due to the tissue distribution of γGT, γ-glutamyl prodrugs
have been mostly developed for kidney applications. An
anti-nociceptive prodrug, γ-glutamyl-dermorphin, was explored
by comparing the pain threshold of mice (Misicka et al., 1996).
More extensively investigated was the γ-glutamyl conjugate of
L-DOPA (dihydroxyphenylalanine). This prodrug provides the
precursor of dopamine, DOPA, upon activation and was explored
as a potential renal vasodilator (Wilk et al., 1978; Worth et al.,
1985; Sadiq et al., 2000). Clinical testingof theprodrugdetermined
that despite reasonable kidney speciﬁcity it had low bioavailability
(Lee, 1990). A number of other compounds were conjugated to a
glutamyl group and tested; however none were approved for use
(Huttunen and Rautio, 2011).
In terms of potential antitumor activity, γ-glutamyl-protected
N-hydroxyguanidines (NHGs) have been developed to explore
the ability to deliver NO to the kidney (Figure 5A). The NHGs
include Nw-hydroxy-L-arginine, which is an intermediate in the
NO synthase synthesis of NO (Zhang et al., 2013b).Whilst promis-
ing results were seen, there was a propensity for the potential
compounds to cyclize (Zhang et al., 2013a,b) suggesting that
NHG conjugation to GSH may be more stable. (Zhang et al.,
2013a). As described above for PABA/NO, JS-K, and GSNO, the
NHGs, in accordance with γGT expression patterns, contribute to
chemotherapy by producing locally high levels of NO which can
rapidly react with O·2− to generate the potent oxidant peroxyni-
trite that, in turn causes extensive cellular damage, including the
nitration of protein tyrosine residues (Kirsch et al., 2001).
Glutamylated phenolic amine compounds have been shown
to be activated by γGT (Figure 5B). γ-L-glutaminyl-4-
hydroxybenzene and γ-L-glutaminyl-4-iodobenzene have been
demonstrated to be activated by tyrosinase (Prezioso et al., 1993)
and γGT (Prezioso et al., 1994a). Both compounds were shown to
have greater cytotoxicity in melanoma cell lines when γGT activity
was not inhibited (Prezioso et al., 1994a).
γGT-activated prodrugs and potential nephrotoxicity
Gamma-glutamyl transferase being the initial and limiting step
in γGT-activated prodrugs processing and because γGT is highly
expressed on the luminal surface of the proximal tubules in the
kidney, potential nephrotoxicity could have been a limitation in
the usage of this class of compound when administered systemat-
ically. In the case of GSAO, a reversible renal toxicity described in
preclinical studies at the maximal tolerated dose was not observed
in human during clinical Phase I (Horsley et al., 2013). Sim-
ilarly, Darinaparsin, when employed in patients (Tsimberidou
et al., 2009; Wu et al., 2010; Hosein et al., 2012) didn’t display any
toxicity proﬁle related to renal dysfunction at dose-limiting toxi-
city (DLT). Taken together, these clinical studies indicate that the
γGT-activated prodrugs have not necessarily nephrotoxic prop-
erties. This type of adverse effects is most likely dependent on
the nature of the metabolites produced by the mercapturic acid
pathway and particularly if the end products are substrates for
cysteine conjugate β-lyases. This enzyme is notably responsible
for the nephrotoxicity of cisplatin (see below). However, recent
studies demonstrated that the modulation of renal GSH content
could prevent such toxicity (Firdous and Kuttan, 2012; Sener et al.,
2012; Ghosh et al., 2013).
β-LYASE AND GENERATION OF CYTOTOXIC PRODUCTS
Cysteine conjugates produced by dipeptidases or amino peptidases
following the GST and γGT steps, are transformed by cysteine
conjugate β-lyases present in the cytosol andmitochondria. The β-
lyases catalyze the β-elimination of various L-cysteine S-conjugates
to the corresponding thiols (Cooper, 1998). The thiols released can
be either toxic or pharmacologically active for the cells responsible
for their production (Commandeur et al., 1995). Due to the high
expression of cysteine conjugate β-lyase in the proximal tubule of
the kidney, administration of cysteine-S-conjugates of haloalkenes
to rodents results in selective nephrotoxicity (Stevens et al., 1989;
Hayden and Stevens, 1990).
The speciﬁc localization along with intense expression of these
enzymes in renal carcinoma has led to the design of kidney-
selective prodrugs that bypass earlier steps of the mercapturic acid
pathway (GST, γGT, and peptidase): these compounds include
S-(guanin-6-yl)-L-cysteine (Elfarra et al., 1995), S-(6-Purinyl)-
L-cysteine (Hwang and Elfarra, 1991; Lash et al., 1997) and
selenocysteine-conjugates (Commandeur et al., 2000; Figure 5C).
The potential of these types of compounds as kidney-selective
antitumor prodrugs has been demonstrated in tissue distribution
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FIGURE 5 | γ-glutamyl conjugates and β-lyase substrates. Activation of N -hydroxyguanidines (A) and glutamylated phenolic amines (B) by γGT. (C) examples
of cysteine- and selenocysteine-conjugates activated by β-elimination catalyzed by β-lyase.
experiments. However, because of a lower ratio of kidney/liver β-
lyase activity in human than rodents, kidney selectivity remains to
be conﬁrmed.
Cisplatin is one of the most effective anticancer agents in the
treatment of solid tumors, including, breast, testicular, and ovar-
ian cancer. The drug binds DNA, which is toxic to dividing tumor
cells. However, therapy with cisplatin is notably limited by a tox-
icity mechanism in the non-dividing proximal tubule cells of the
kidney that is distinct from DNA cross-linking. It was demon-
strated that cysteine S-conjugate β-lyase highly expressed in the
kidney was responsible for the observed nephrotoxicity (Zhang
and Hanigan, 2003; Townsend et al., 2003). Even if cysteine S-
conjugate β-lyase is responsible for the synthesis of the highly
reactive and cytotoxic thiol version of cisplatin (Figure 1), the
activation of cisplatin into a nephrotoxin relies on the three pre-
vious steps of the classical mercapturic acid pathway involving
GSTs (GSH conjugation), γGT (production of CisPt-cys-glu) and
dipeptidase (production of CisPt-cys; Figure 5C). Indeed, the
inhibition of γGT or cysteine S-conjugate β-lyase (both highly
expressed in proximal tubule cells of the kidney) blocks the
nephrotoxicity of cisplatin in mice (Townsend et al., 2003). In this
process, the action of γGT is a key and limiting step as it trans-
formed the essentially membrane impermeable CisPt-GSH into a
membrane permeable CisPt-cys-glu that can be taken up by the
cells.
CONCLUSION
The traditional approach to identify potential cancer therapies
has been to identify a drug that helps the greatest number of
patients. In doing this, the potential of therapies that have a sig-
niﬁcant impact on a small subset is lost within the larger sample
population. The current trend to target speciﬁc abnormalities in
cancer allows for the development of predictive markers and com-
panion tests to identify which patients have a particular tumor
characteristic. From this stems the ability to identify the patient
population that will (or will not) respond to the drug. Developing
new therapies with the target population in mind will facilitate the
development of drugs that will induce a greater tumor response
for individual patients. For this to occur, a marker that predicts
patient response to the drug is essential.
This review recapitulates the different drug strategies involving
GSH-conjugates, and the enzymes of the mercapturic acid path-
way, employed over the last twenty years. Amongst the long list of
compounds investigated, a limited number of GSH-conjugates
have recently progressed towards clinical trials for the treat-
ment of cancer patients. Both GST-activated nitrogen mustard
(TLK286) and γGT-activated arsenic-based (GSAO and Darina-
parsin) prodrugs have displayed promising activities along with
safe proﬁles.
Given the complexity of mechanisms involved in drug resis-
tance and survival pathways of tumor cells, combination strategies
of GSH-conjugates with conventional chemotherapy or targeted
drugs should provide very interesting perspectives for the treat-
ment of drug resistant tumors. This approach has already been
explored successfully with TLK286 when combined with pegy-
lated liposomal doxorubicin (Kavanagh et al., 2010; Vergote et al.,
2010) or with carboplatin plus paclitaxel (Sequist et al., 2009).
Moreover, knowing that the combinations of arsenic trioxide with
targeted drugs such as mTOR (Guilbert et al., 2013; Iwanami et al.,
2013), EGFR (Noh et al., 2010; Kryeziu et al., 2013), or proteasome
inhibitors (Jung et al., 2012) demonstrate potent proﬁles on a vari-
ety of malignancies, it would be of great interest to investigate the
antitumor properties of such inhibitors in combination with the
arsenical-based GSH-conjugates GSAO and Darinaparsin.
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Increased GST and/or γGT tumor expression, generally con-
sidered as a bad prognosis marker (associated with drug resistance
and disease progression), and could potentially be used as a pre-
dictive marker, allowing doctors, after biopsy, to identify which
patients will respond best to GST or γGT-activated prodrugs.
Predictive biomarkers provide a number of beneﬁts, includ-
ing: reduced unnecessary treatment; reduced quantity of adverse
events; reduced drug attrition rates; improved therapeutic ben-
eﬁt; and better control of medical costs (La Thangue and Kerr,
2011). Whilst taking the time to test for GST and/or γGT tumor
expression may slightly delay treatment, it will ensure that GSH-
conjugates anticancer prodrugswill be administered to thepatients
that are more likely to respond.
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